Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Predicting outcomes and complications following radioiodine therapy in Graves' thyrotoxicosis.

Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW.

Clin Endocrinol (Oxf). 2019 Jan;90(1):192-199. doi: 10.1111/cen.13873. Epub 2018 Oct 25.

PMID:
30291728
2.

Diurnal profile of interstitial glucose following dexamethasone prophylaxis for chemotherapy treatment of gynaecological cancer.

Lyall MJ, Thethy I, Steven L, MacKean M, Nussey F, Sakala M, Rye T, Strachan MWJ, Dover AR.

Diabet Med. 2018 Nov;35(11):1508-1514. doi: 10.1111/dme.13770. Epub 2018 Aug 3.

PMID:
29938852
3.

Decreased iron stores are associated with cardiovascular disease in patients with type 2 diabetes both cross-sectionally and longitudinally.

Suárez-Ortegón MF, McLachlan S, Price AH, Fernández-Balsells M, Franch-Nadal J, Mata-Cases M, Barrot-de la Puente J, Mundet-Tudurí X, Mauricio D, Ricart W, Wild SH, Strachan MWJ, Price JF, Fernández-Real JM.

Atherosclerosis. 2018 May;272:193-199. doi: 10.1016/j.atherosclerosis.2018.03.028. Epub 2018 Mar 21.

PMID:
29625295
4.

Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial.

Reynolds RM, Denison FC, Juszczak E, Bell JL, Penneycard J, Strachan MWJ, Lindsay RS, Alexander CI, Love CDB, Whyte S, Mackenzie F, Stenson B, Norman JE.

BMC Pregnancy Childbirth. 2017 Sep 22;17(1):316. doi: 10.1186/s12884-017-1505-3.

5.

Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study.

Price AH, Weir CJ, Welsh P, McLachlan S, Strachan MWJ, Sattar N, Price JF.

Atherosclerosis. 2017 Sep;264:67-73. doi: 10.1016/j.atherosclerosis.2017.07.009. Epub 2017 Jul 12.

6.

Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes.

Jenks SJ, Conway BR, McLachlan S, Teoh WL, Williamson RM, Webb DJ, Welsh P, Sattar N, Strachan MWJ, Price JF.

Diabetologia. 2017 Aug;60(8):1400-1408. doi: 10.1007/s00125-017-4297-0. Epub 2017 May 20.

7.

Fatal haemorrhage following fine needle aspiration of the thyroid.

Strachan MW, Dalvi M, Ainsworth R, Gibb FW, Horsfall H, Patel D.

J R Coll Physicians Edinb. 2016 Sep;46(3):166-167. doi: 10.4997/JRCPE.2016.306.

PMID:
27959351
8.

BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.

Greenhalgh KA, Strachan MW, Alzahrani S, Baxter PD, Standeven KF, Storey RF, Ariens RA, Grant PJ, Price JF, Ajjan RA.

Thromb Haemost. 2017 Jan 26;117(2):295-302. doi: 10.1160/TH16-07-0554. Epub 2016 Dec 8.

9.

Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.

Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl JR, Gibb FW.

Thyroid. 2016 Aug;26(8):1004-9. doi: 10.1089/thy.2016.0017. Epub 2016 Jul 6.

PMID:
27266892
10.

Adrenal insufficiency in patients on long-term opioid analgesia.

Gibb FW, Stewart A, Walker BR, Strachan MW.

Clin Endocrinol (Oxf). 2016 Dec;85(6):831-835. doi: 10.1111/cen.13125. Epub 2016 Jun 28.

PMID:
27260138
11.

Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes.

Betz BB, Jenks SJ, Cronshaw AD, Lamont DJ, Cairns C, Manning JR, Goddard J, Webb DJ, Mullins JJ, Hughes J, McLachlan S, Strachan MWJ, Price JF, Conway BR.

Kidney Int. 2016 May;89(5):1125-1135. doi: 10.1016/j.kint.2016.01.015. Epub 2016 Mar 7.

PMID:
27083286
12.

Coronary artery spasm secondary to carcinoid syndrome.

Fenning SJ, Newby DE, Toumpanakis C, Strachan MW.

QJM. 2016 Jul;109(7):483-4. doi: 10.1093/qjmed/hcw050. Epub 2016 Mar 25. No abstract available.

PMID:
27016533
13.

Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis.

White J, Sofat R, Hemani G, Shah T, Engmann J, Dale C, Shah S, Kruger FA, Giambartolomei C, Swerdlow DI, Palmer T, McLachlan S, Langenberg C, Zabaneh D, Lovering R, Cavadino A, Jefferis B, Finan C, Wong A, Amuzu A, Ong K, Gaunt TR, Warren H, Davies TL, Drenos F, Cooper J, Ebrahim S, Lawlor DA, Talmud PJ, Humphries SE, Power C, Hypponen E, Richards M, Hardy R, Kuh D, Wareham N, Ben-Shlomo Y, Day IN, Whincup P, Morris R, Strachan MW, Price J, Kumari M, Kivimaki M, Plagnol V, Whittaker JC; International Consortium for Blood Pressure (ICBP), Smith GD, Dudbridge F, Casas JP, Holmes MV, Hingorani AD; UCLEB (University College London-London School of Hygiene & Tropical Medicine-Edinburgh-Bristol Consortium.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):327-36. doi: 10.1016/S2213-8587(15)00386-1. Epub 2016 Jan 16.

14.

The prevalence of structural pituitary abnormalities by MRI scanning in men presenting with isolated hypogonadotrophic hypogonadism.

Dalvi M, Walker BR, Strachan MW, Zammitt NN, Gibb FW.

Clin Endocrinol (Oxf). 2016 Jun;84(6):858-61. doi: 10.1111/cen.13015. Epub 2016 Feb 12.

PMID:
26733239
15.

Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Morling JR, Fallowfield JA, Guha IN, Williamson RM, Ali M, Glancy S, Strachan MW, Price JF.

QJM. 2016 Apr;109(4):249-56. doi: 10.1093/qjmed/hcv191. Epub 2015 Oct 9.

16.

The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors.

Feinkohl I, Price JF, Strachan MW, Frier BM.

Alzheimers Res Ther. 2015 Jun 10;7(1):46. doi: 10.1186/s13195-015-0130-5. eCollection 2015.

17.

Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis.

Nüesch E, Dale C, Palmer TM, White J, Keating BJ, van Iperen EP, Goel A, Padmanabhan S, Asselbergs FW; EPIC-Netherland Investigators, Verschuren WM, Wijmenga C, Van der Schouw YT, Onland-Moret NC, Lange LA, Hovingh GK, Sivapalaratnam S, Morris RW, Whincup PH, Wannamethe GS, Gaunt TR, Ebrahim S, Steel L, Nair N, Reiner AP, Kooperberg C, Wilson JF, Bolton JL, McLachlan S, Price JF, Strachan MW, Robertson CM, Kleber ME, Delgado G, März W, Melander O, Dominiczak AF, Farrall M, Watkins H, Leusink M, Maitland-van der Zee AH, de Groot MC, Dudbridge F, Hingorani A, Ben-Shlomo Y, Lawlor DA; UCLEB Investigators, Amuzu A, Caufield M, Cavadino A, Cooper J, Davies TL; IN Day, Drenos F, Engmann J, Finan C, Giambartolomei C, Hardy R, Humphries SE, Hypponen E, Kivimaki M, Kuh D, Kumari M, Ong K, Plagnol V, Power C, Richards M, Shah S, Shah T, Sofat R, Talmud PJ, Wareham N, Warren H, Whittaker JC, Wong A, Zabaneh D, Davey Smith G, Wells JC, Leon DA, Holmes MV, Casas JP.

Int J Epidemiol. 2016 Dec 1;45(6):1927-1937. doi: 10.1093/ije/dyv074.

18.

Cardiovascular risk factors and cognitive decline in older people with type 2 diabetes.

Feinkohl I, Keller M, Robertson CM, Morling JR, McLachlan S, Frier BM, Deary IJ, Strachan MW, Price JF.

Diabetologia. 2015 Jul;58(7):1637-45. doi: 10.1007/s00125-015-3581-0. Epub 2015 Apr 7.

19.

γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study.

Morling JR, Fallowfield JA, Williamson RM, Robertson CM, Glancy S, Guha IN, Strachan MW, Price JF.

Diabetologia. 2015 Jul;58(7):1484-93. doi: 10.1007/s00125-015-3575-y. Epub 2015 Mar 29.

20.

Sixty-five common genetic variants and prediction of type 2 diabetes.

Talmud PJ, Cooper JA, Morris RW, Dudbridge F, Shah T, Engmann J, Dale C, White J, McLachlan S, Zabaneh D, Wong A, Ong KK, Gaunt T, Holmes MV, Lawlor DA, Richards M, Hardy R, Kuh D, Wareham N, Langenberg C, Ben-Shlomo Y, Wannamethee SG, Strachan MW, Kumari M, Whittaker JC, Drenos F, Kivimaki M, Hingorani AD, Price JF, Humphries SE; UCLEB Consortium.

Diabetes. 2015 May;64(5):1830-40. doi: 10.2337/db14-1504. Epub 2014 Dec 4.

21.

Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study.

Bedenis R, Price AH, Robertson CM, Morling JR, Frier BM, Strachan MW, Price JF.

Diabetes Care. 2014 Dec;37(12):3301-8. doi: 10.2337/dc14-0908. Epub 2014 Sep 19.

PMID:
25239782
22.

N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Price AH, Welsh P, Weir CJ, Feinkohl I, Robertson CM, Morling JR, McLachlan S, Strachan MW, Sattar N, Price JF.

Diabetologia. 2014 Dec;57(12):2505-12. doi: 10.1007/s00125-014-3375-9. Epub 2014 Sep 18.

PMID:
25231020
23.

Genome wide association identifies common variants at the SERPINA6/SERPINA1 locus influencing plasma cortisol and corticosteroid binding globulin.

Bolton JL, Hayward C, Direk N, Lewis JG, Hammond GL, Hill LA, Anderson A, Huffman J, Wilson JF, Campbell H, Rudan I, Wright A, Hastie N, Wild SH, Velders FP, Hofman A, Uitterlinden AG, Lahti J, Räikkönen K, Kajantie E, Widen E, Palotie A, Eriksson JG, Kaakinen M, Järvelin MR, Timpson NJ, Davey Smith G, Ring SM, Evans DM, St Pourcain B, Tanaka T, Milaneschi Y, Bandinelli S, Ferrucci L, van der Harst P, Rosmalen JG, Bakker SJ, Verweij N, Dullaart RP, Mahajan A, Lindgren CM, Morris A, Lind L, Ingelsson E, Anderson LN, Pennell CE, Lye SJ, Matthews SG, Eriksson J, Mellstrom D, Ohlsson C, Price JF, Strachan MW, Reynolds RM, Tiemeier H, Walker BR; CORtisol NETwork (CORNET) Consortium.

PLoS Genet. 2014 Jul 10;10(7):e1004474. doi: 10.1371/journal.pgen.1004474. eCollection 2014 Jul.

24.

Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3.

Hess K, Alzahrani SH, Price JF, Strachan MW, Oxley N, King R, Gamlen T, Schroeder V, Baxter PD, Ajjan RA.

Diabetologia. 2014 Aug;57(8):1737-41. doi: 10.1007/s00125-014-3267-z. Epub 2014 May 17.

PMID:
24838681
25.

Androgen deficiency and type 2 diabetes mellitus.

Gibb FW, Strachan MW.

Clin Biochem. 2014 Jul;47(10-11):940-9. doi: 10.1016/j.clinbiochem.2014.04.004. Epub 2014 Apr 24. Review.

PMID:
24768826
26.

Diabetes. Cognitive decline and T2DM--a disconnect in the evidence?

Strachan MW, Price JF.

Nat Rev Endocrinol. 2014 May;10(5):258-60. doi: 10.1038/nrendo.2014.38. Epub 2014 Apr 1.

PMID:
24686200
27.

Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes.

Jenks SJ, Conway BR, Hor TJ, Williamson RM, McLachlan S, Robertson C, Morling JR, Strachan MW, Price JF.

Diabet Med. 2014 Sep;31(9):1039-46. doi: 10.1111/dme.12456. Epub 2014 Apr 16.

PMID:
24684407
28.

Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions.

Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA.

Lancet Diabetes Endocrinol. 2014 Mar;2(3):246-55. doi: 10.1016/S2213-8587(13)70088-3. Epub 2013 Oct 18. Review.

PMID:
24622755
29.

Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study.

Morling JR, Fallowfield JA, Guha IN, Nee LD, Glancy S, Williamson RM, Robertson CM, Strachan MW, Price JF; Edinburgh Type 2 Diabetes Study investigators.

J Hepatol. 2014 Feb;60(2):384-91. Epub 2013 Oct 26.

PMID:
24512822
30.

Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study.

Morling JR, Fallowfield JA, Williamson RM, Nee LD, Jackson AP, Glancy S, Reynolds RM, Hayes PC, Guha IN, Strachan MW, Price JF.

Liver Int. 2014 Sep;34(8):1267-77. doi: 10.1111/liv.12385. Epub 2013 Dec 3.

PMID:
24237940
31.

Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes.

Anderssohn M, McLachlan S, Lüneburg N, Robertson C, Schwedhelm E, Williamson RM, Strachan MW, Ajjan R, Grant PJ, Böger RH, Price JF.

Diabetes Care. 2014;37(3):846-54. doi: 10.2337/dc13-0546. Epub 2013 Nov 1.

PMID:
24186881
32.

Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study.

Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, McLachlan S, Deary IJ, Frier BM, Strachan MW, Price JF; Edinburgh Type 2 Diabetes Study (ET2DS) Investigators.

Diabetes Care. 2014 Feb;37(2):507-15. doi: 10.2337/dc13-1384. Epub 2013 Oct 8.

PMID:
24103900
33.

Association between excessive daytime sleepiness and severe hypoglycemia in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Inkster B, Riha RL, Van Look L, Williamson R, McLachlan S, Frier BM, Strachan MW, Price JF, Reynolds RM.

Diabetes Care. 2013 Dec;36(12):4157-9. doi: 10.2337/dc13-0863. Epub 2013 Oct 2.

34.

Population genomics of cardiometabolic traits: design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium.

Shah T, Engmann J, Dale C, Shah S, White J, Giambartolomei C, McLachlan S, Zabaneh D, Cavadino A, Finan C, Wong A, Amuzu A, Ong K, Gaunt T, Holmes MV, Warren H, Swerdlow DI, Davies TL, Drenos F, Cooper J, Sofat R, Caulfield M, Ebrahim S, Lawlor DA, Talmud PJ, Humphries SE, Power C, Hypponen E, Richards M, Hardy R, Kuh D, Wareham N, Langenberg C, Ben-Shlomo Y, Day IN, Whincup P, Morris R, Strachan MW, Price J, Kumari M, Kivimaki M, Plagnol V, Dudbridge F, Whittaker JC, Casas JP, Hingorani AD; UCLEB Consortium.

PLoS One. 2013 Aug 20;8(8):e71345. doi: 10.1371/journal.pone.0071345. eCollection 2013. Erratum in: PLoS One. 2014;8(9): doi/10.1371/annotation/89b51e89-a415-49c7-9caa-8dfcf6fde855. Swerdlow, Daniel I [added]; Langenberg, Claudia [added].

35.

Discordance in thyroglobulin measurements by radioimmunoassay and immunometric assay: a useful means of identifying thyroglobulin assay interference.

Crane MS, Strachan MW, Toft AD, Beckett GJ.

Ann Clin Biochem. 2013 Sep;50(Pt 5):421-32. doi: 10.1177/0004563213480492. Epub 2013 Jul 11.

PMID:
23847033
36.

Predictors of treatment failure, incipient hypothyroidism, and weight gain following radioiodine therapy for Graves' thyrotoxicosis.

Gibb FW, Zammitt NN, Beckett GJ, Strachan MW.

J Endocrinol Invest. 2013 Oct;36(9):764-9. doi: 10.3275/8949. Epub 2013 Apr 30.

PMID:
23633646
37.

Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Feinkohl I, Keller M, Robertson CM, Morling JR, Williamson RM, Nee LD, McLachlan S, Sattar N, Welsh P, Reynolds RM, Russ TC, Deary IJ, Strachan MW, Price JF; Edinburgh Type 2 Diabetes Study (ET2DS) Investigators.

Diabetes Care. 2013 Sep;36(9):2779-86. doi: 10.2337/dc12-2241. Epub 2013 Apr 11.

38.

Metabolic parameters associated with arterial stiffness in older adults with Type 2 diabetes: the Edinburgh Type 2 diabetes study.

Teoh WL, Price JF, Williamson RM, Payne RA, Van Look LA, Reynolds RM, Frier BM, Wilkinson IB, Webb DJ, Strachan MW; ET2DS Investigators.

J Hypertens. 2013 May;31(5):1010-7. doi: 10.1097/HJH.0b013e32835f7ecf. Erratum in: J Hypertens. 2013 Jul;31(7):1497.

PMID:
23492645
39.

Mutations in HNF1A result in marked alterations of plasma glycan profile.

Thanabalasingham G, Huffman JE, Kattla JJ, Novokmet M, Rudan I, Gloyn AL, Hayward C, Adamczyk B, Reynolds RM, Muzinic A, Hassanali N, Pucic M, Bennett AJ, Essafi A, Polasek O, Mughal SA, Redzic I, Primorac D, Zgaga L, Kolcic I, Hansen T, Gasperikova D, Tjora E, Strachan MW, Nielsen T, Stanik J, Klimes I, Pedersen OB, Njølstad PR, Wild SH, Gyllensten U, Gornik O, Wilson JF, Hastie ND, Campbell H, McCarthy MI, Rudd PM, Owen KR, Lauc G, Wright AF.

Diabetes. 2013 Apr;62(4):1329-37. doi: 10.2337/db12-0880. Epub 2012 Dec 28.

40.

Association of N-terminal pro-brain natriuretic peptide with cognitive function and depression in elderly people with type 2 diabetes.

Feinkohl I, Sattar N, Welsh P, Reynolds RM, Deary IJ, Strachan MW, Price JF; Edinburgh Type 2 Diabetes Study-ET2DS Investigators.

PLoS One. 2012;7(9):e44569. Epub 2012 Sep 4.

41.

Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors.

Conway BR, Manoharan D, Manoharan D, Jenks S, Dear JW, McLachlan S, Strachan MW, Price JF.

Kidney Int. 2012 Oct;82(7):812-8. doi: 10.1038/ki.2012.218. Epub 2012 Jun 20.

42.

Serum leptin and cognitive function in people with type 2 diabetes.

Labad J, Price JF, Strachan MW, Deary IJ, Seckl JR, Sattar N, Reynolds RM; Edinburgh Type 2 Diabetes Study Investigators.

Neurobiol Aging. 2012 Dec;33(12):2938-2941.e2. doi: 10.1016/j.neurobiolaging.2012.02.026. Epub 2012 Apr 3.

PMID:
22475620
43.

Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study.

Reynolds RM, Labad J, Sears AV, Williamson RM, Strachan MW, Deary IJ, Lowe GD, Price JF, Walker BR; Edinburgh Type 2 Diabetes study investigators.

Eur J Endocrinol. 2012 May;166(5):861-8. doi: 10.1530/EJE-12-0041. Epub 2012 Mar 9.

44.

Leptin levels and depressive symptoms in people with type 2 diabetes: the edinburgh type 2 diabetes study.

Labad J, Price JF, Strachan MW, Fowkes FG, Deary IJ, Seckl JR, Walker BR, Sattar N, Reynolds RM; Edinburgh Type 2 Diabetes Study Investigators.

Psychosom Med. 2012 Jan;74(1):39-45. doi: 10.1097/PSY.0b013e31823ba8af. Epub 2011 Dec 30.

PMID:
22210236
45.

Prevalence and markers of advanced liver disease in type 2 diabetes.

Williamson RM, Price JF, Hayes PC, Glancy S, Frier BM, Johnston GI, Reynolds RM, Strachan MW; Edinburgh Type 2 Diabetes Study Investigators.

QJM. 2012 May;105(5):425-32. doi: 10.1093/qjmed/hcr233. Epub 2011 Dec 7.

PMID:
22156706
46.

Severe hypoglycaemia and late-life cognitive ability in older people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Aung PP, Strachan MW, Frier BM, Butcher I, Deary IJ, Price JF; Edinburgh Type 2 Diabetes Study Investigators.

Diabet Med. 2012 Mar;29(3):328-36. doi: 10.1111/j.1464-5491.2011.03505.x.

PMID:
22023662
47.

Prevalence of abnormal plasma liver enzymes in older people with Type 2 diabetes.

Morling JR, Strachan MW, Hayes PC, Butcher I, Frier BM, Reynolds RM, Price JF; Edinburgh Type 2 Diabetes Study investigators.

Diabet Med. 2012 Apr;29(4):488-91. doi: 10.1111/j.1464-5491.2011.03492.x.

PMID:
22004335
48.

A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3.

Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter AM, Howell G, Koko T, Strachan MW, Price JF, Smith KA, Grant PJ, Ajjan RA.

Diabetologia. 2012 Apr;55(4):1103-13. doi: 10.1007/s00125-011-2301-7. Epub 2011 Sep 15.

PMID:
21918806
49.

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW; Edinburgh Type 2 Diabetes Study Investigators.

Diabetes Care. 2011 May;34(5):1139-44. doi: 10.2337/dc10-2229. Epub 2011 Apr 8.

50.

Association of retinal arteriolar dilatation with lower verbal memory: the Edinburgh Type 2 Diabetes Study.

Ding J, Strachan MW, Fowkes FG, Wong TY, Macgillivray TJ, Patton N, Gardiner TA, Deary IJ, Price JF.

Diabetologia. 2011 Jul;54(7):1653-62. doi: 10.1007/s00125-011-2129-1. Epub 2011 Apr 1.

PMID:
21455727

Supplemental Content

Loading ...
Support Center